Ascendia

 

  MARKET NEWS

Gyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis
Galatea Bio Secures $25M to Develop Global Biobank & Enable Precision Health at Scale for All
NeOnc Technologies Expands Global Clinical Trial Network With CBCC Global Research to Accelerate Study of Brain Cancer Treatments
CERo Therapeutics Holdings Poised to Initiate Enrollment of Phase 1 Trial of CER-1236 in AML Following Positive FDA Review of Manufacturing
Polyrizon Structures Clinical Strategy for its Allergy Blocker Ahead of FDA Pre-Submission Meeting
Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces its Novel Inhibitors Show Promising In Silico Activity Against Measles & Related Viruses
Acumen Pharmaceuticals Completes Enrollment of Phase 2 Clinical Trial of Sabirnetug in Early Alzheimer’s Disease
Bluejay Therapeutics Announces First Patient Dosed in AZURE-1 Global Pivotal Clinical Trial Evaluating Brelovitug as a Monotherapy Treatment for Chronic Hepatitis D
Silo Pharma Achieves Key Milestone With First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment
Enable Injections Announces Regulatory CE Mark Approval in Europe for enFuse Technology

  EXPERT CONTENT & RESOURCES

 

How to Choose the Right CDMO for Your Pharmaceutical Project

How to Choose the Right CDMO for Your Pharmaceutical Project

This guide outlines the fundamental considerations to ensure your CDMO selection aligns with your project goals.

Understanding the Foundation of LNP Formulation Success

Understanding the Foundation of LNP Formulation Success

Download our eBook and discover everything you need to know about lipids for developing LNP therapies, including:….

Lyophilization Development: Quality by Design Approach

Lyophilization Development: Quality by Design Approach

Lyophilization, or freeze-drying, addresses stability challenges associated with complex APIs, biologics, microbiomes, gene therapies, viral vectors, liposomes, and nanoparticles……

Choosing the Right Particle for Your Nanomedicine Application

Choosing the Right Particle for Your Nanomedicine Application

Nanoparticles are revolutionizing the landscape of nanomedicine, enabling significant advancements in early detection, targeted drug delivery, disease monitoring, and imaging. Due to their nanoscale size, these particles….

  FEATURED EDITORIAL

  COMPANY PROFILE

ProMed Pharma is your distinguished development partner in long-acting injectable and implantable dosage forms. With nearly 20 years of operational history, we have honed our expertise in polymer-based dosage forms, achieving mastery in extended-release dosing. Our proficiency spans molding, extrusion, and microencapsulation techniques, leveraging a diverse spectrum of polymeric excipients encompassing silicones, thermoplastics, and biodegradables. At ProMed Pharma, our commitment to rapid project execution is underpinned by a steadfast dedication to scientific inquiry and technical finesse. Whether you represent an emerging biotech venture or a global pharmaceutical entity, entrust us as your CDMO partner, as we diligently translate scientific concepts into finished dosage forms. Click here for more.

Click image to see Captisol’s latest video

  WHITEPAPERS & WEBINARS

WEBINAR ON DEMAND: Precision at Scale: Enabling Novel Therapeutics With Nanoparticle Manufacturing

WEBINAR ON DEMAND: Precision at Scale: Enabling Novel Therapeutics With Nanoparticle Manufacturing

Watch this on-demand webinar to learn about the key steps and considerations in bringing novel nanoparticle-based therapeutics from early R&D to commercial stages. Drawing from our 20 years of experience in the CDMO space, we cover critical topics unique to nanomaterials…..

WEBINAR ON DEMAND: Advantages of Carbopol® Polymers in Oral Formulations

WEBINAR ON DEMAND: Advantages of Carbopol® Polymers in Oral Formulations

In this video, the Lubrizol team together with the IMCD US team takes you through formulation aspects of Carbopol® polymers as well as the results of a case study on an Acetaminophen oral suspension formulation.

  WHITEPAPERS & WEBINARS

 

WHITEPAPER - 3D SCREEN Printing: Enabling a New Generation of Complex Formulations

WHITEPAPER - 3D SCREEN Printing: Enabling a New Generation of Complex Formulations

The pharmaceutical industry has been acquainted with the promise of 3D printing for some time now, with many large pharma companies exploring the possibilities of the technology. However, 3D-printed pharmaceuticals have been largely relegated to niche markets and prototyping due …

 WHITEPAPER - Formulating Custom Viscosity Blends With POLYOX™ Polyethylene Oxide 

 WHITEPAPER - Formulating Custom Viscosity Blends With POLYOX™ Polyethylene Oxide 


Excipient variability plays a critical role in pharmaceutical product design. A risk-based, scientific approach to Quality by Design (QbD) is essential to ensure consistent drug performance.

Our latest whitepaper delves into the impact of POLYOX™ PEO (Polyethylene Oxide) on drug …

WHITEPAPER - Versatility of Geleol™ Mono- and Diglycerides NF

WHITEPAPER - Versatility of Geleol™ Mono- and Diglycerides NF

By: Jasmine Musakhanian, Senior Scientific Director, Gattefossé

INTRODUCTION

Mono and diglycerides, also known as partial glycerides, are versatile lipid excipients that play a pivotal role in the realization of drug products and nutraceuticals. Some well-known excipients in this category are …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

April 9 – Formulation Development
April 16 – Prefilled Syringes